| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8315.6B | ¥7722.4B | +7.7% |
| Operating Income | ¥1448.7B | ¥1335.0B | +8.5% |
| Profit Before Tax | ¥1465.9B | ¥1318.3B | +11.2% |
| Net Income | ¥1095.5B | ¥986.2B | +11.1% |
| ROE | 7.2% | 7.2% | - |
FY2026 Q3 cumulative results: Revenue reached 831.6B yen (YoY +7.7%), Operating Income 144.9B yen (+8.5%), Ordinary Income 146.6B yen (+11.2%), and Net Income 109.5B yen (+11.1%), marking consecutive revenue and profit growth. Operating margin improved to 17.4% (+0.1pt from 17.3% YoY), while net profit margin expanded to 13.2% (+0.4pt from 12.8% YoY). The company completed the acquisition of OrganOx during the quarter, adding a fourth reportable segment. Despite strong profitability metrics, operating cash flow decreased slightly by 1.6% to 141.9B yen, while free cash flow turned significantly negative at -173.8B yen due to substantial investing activities totaling -315.7B yen, primarily related to M&A transactions.
Revenue increased 59.3B yen (+7.7% YoY) driven by growth across all major segments. The Cardiac and Vascular Company, representing 59.7% of total revenue, grew 32.6B yen (+7.0% YoY) to 496.8B yen, maintaining its position as the core business. The Medical Care Solutions Company contributed 163.2B yen (+3.5B yen, +2.2% YoY), while the Blood and Cell Technologies Company delivered strong performance at 168.5B yen (+20.4B yen, +13.7% YoY). The newly acquired OrganOx segment contributed 2.9B yen in its first reporting period. Foreign exchange effects positively impacted results as indicated by FX gains of 12.3B yen in cash flow statements.
Operating income grew 11.4B yen (+8.5% YoY) to 144.9B yen, with operating margin expanding 0.1pt to 17.4%. Gross profit margin remained robust at 53.6% (unchanged YoY), while SG&A expenses increased 14.0B yen to 295.1B yen, representing 35.5% of revenue (+0.1pt YoY). The company incurred non-recurring expenses of 11.5B yen during the quarter, including business restructuring costs of 7.9B yen and impairment losses of 4.8B yen related to a discontinued pharmaceutical manufacturing project, along with associated costs of 3.4B yen and acquisition-related expenses of 3.3B yen.
Net income reached 109.5B yen (+11.1% YoY), outpacing operating income growth due to improved financial income (+1.5B yen to 4.1B yen) and reduced financial costs (-2.1B yen to 1.8B yen), resulting in net financial income of 2.4B yen versus -1.2B yen in the prior year. The effective tax rate was 25.3%, consistent with 25.2% in the prior period. This represents a revenue up/profit up pattern, with bottom-line growth (+11.1%) exceeding top-line growth (+7.7%), indicating operational leverage and improved cost efficiency despite one-time charges.
The Cardiac and Vascular Company generated revenue of 496.8B yen (+7.0% YoY) with operating income of 129.3B yen (+9.6% YoY), delivering an industry-leading segment margin of 26.0% (+0.6pt YoY). This segment remains the core business, accounting for 59.7% of consolidated revenue and 74.1% of total segment profit. The Medical Care Solutions Company posted revenue of 163.2B yen (+2.2% YoY) with operating income of 19.7B yen (+2.7% YoY), maintaining a margin of 12.1% (+0.1pt YoY). The Blood and Cell Technologies Company achieved revenue of 168.5B yen (+13.7% YoY) with operating income of 25.2B yen (+27.4% YoY), improving its margin to 15.0% (+1.5pt YoY), representing the strongest profitability improvement among established segments. The newly consolidated OrganOx segment contributed revenue of 2.9B yen with operating income of 0.5B yen, achieving an 18.1% margin in its initial reporting period. Material margin differences exist between segments, with the Cardiac and Vascular Company's 26.0% margin significantly exceeding the Medical Care Solutions Company's 12.1% margin, reflecting differences in product mix and competitive dynamics.
[Profitability] ROE stands at 7.2%, calculated through DuPont decomposition as net profit margin 13.2% multiplied by asset turnover 0.368 and financial leverage 1.48x. While net profit margin remains healthy, asset turnover of 0.368 falls below the industry median of 0.56, indicating lower asset efficiency. Operating margin of 17.4% (+0.1pt YoY) significantly exceeds the industry median of 8.9%, positioning the company in the top quartile for operational profitability. Basic EPS improved to 74.27 yen (+11.6% YoY) from 66.53 yen. [Cash Quality] Cash and equivalents totaled 238.0B yen at quarter-end, representing 0.08x coverage of short-term bonds and borrowings of 299.8B yen, indicating constrained short-term liquidity. Operating cash flow of 141.9B yen represents 1.30x net income, confirming strong cash-backed earnings quality. [Investment Efficiency] Asset turnover of 0.368 declined from higher levels due to substantial asset base expansion, primarily from M&A-related intangible assets which increased 255.3B yen (+46.8%) to 800.5B yen. [Financial Health] Equity ratio of 67.5% exceeds the industry median of 63.8%, indicating a conservative capital structure. However, current liabilities surged 298.7B yen (+123.9%) to 539.7B yen, driven primarily by short-term bonds and borrowings increasing from 15.0B yen to 299.8B yen, raising near-term refinancing considerations.
Operating cash flow of 141.9B yen represents 1.30x net income, confirming healthy cash conversion from earnings. The operating cash flow subtotal before working capital changes was 179.8B yen, with working capital absorption of approximately 37.9B yen primarily driven by inventory increases of 10.8B yen and receivables increases of 24.3B yen. Income taxes paid totaled 39.1B yen, interest paid 1.9B yen, and lease payments 5.9B yen. Investing cash flow of -315.7B yen was dominated by M&A-related payments, particularly the OrganOx acquisition, alongside capital expenditures of 50.0B yen. Financing cash flow of 177.6B yen reflected net borrowing increases to fund acquisitions, offset by dividend payments of 41.2B yen. Free cash flow of -173.8B yen indicates the company prioritized growth investments over cash generation in this period. Cash position increased 16.1B yen to 238.0B yen despite negative FCF, supported by debt financing. The company's cash coverage of short-term liabilities at 0.44x suggests potential liquidity pressure requiring monitoring, though access to capital markets remains evident through successful debt issuance.
Operating income of 144.9B yen compared to profit before tax of 146.6B yen shows a modest net non-operating contribution of approximately 1.7B yen. This comprises financial income of 4.1B yen (primarily interest and dividend income) offset by financial costs of 1.8B yen and equity method losses of 0.6B yen. Non-operating items represent less than 1% of revenue, indicating earnings are predominantly driven by core operations. The company recorded non-recurring charges totaling 11.5B yen during the quarter, including business restructuring costs, impairment losses, and acquisition-related expenses, which should be excluded when assessing normalized profitability. On an adjusted basis, the company reports adjusted operating income (segment profit) of 173.5B yen before amortization of acquired intangibles (17.1B yen) and non-recurring items (11.5B yen), representing an adjusted operating margin of 20.9%. Operating cash flow of 141.9B yen exceeds net income of 109.5B yen, yielding a cash conversion ratio of 1.30x, which significantly surpasses the industry median of 0.94x, indicating superior earnings quality with strong cash realization.
Progress against full-year guidance shows revenue achievement at 75.0% (831.6B yen vs. 1,108.0B yen forecast), operating income at 79.8% (144.9B yen vs. 181.5B yen forecast), both tracking ahead of the standard Q3 benchmark of 75%. This suggests the company is positioned to meet or potentially exceed full-year targets. The guidance assumes operating income growth of 15.1% YoY, which would represent an acceleration from the 8.5% growth achieved through Q3, implying a strong Q4 performance expectation. No forecast revisions were announced during the quarter despite the OrganOx acquisition, indicating management confidence in absorbing integration costs while maintaining guidance. The forecast assumes an annual dividend of 15.00 yen per share and EPS of 92.20 yen, implying a payout ratio of 16.3% on forecasted earnings.
The company declared an interim dividend of 13.00 yen per share, with a planned year-end dividend of 13.00 yen, totaling 15.00 yen for the full year (unchanged from prior year). Based on net income of 109.5B yen for the nine-month period and average shares outstanding of 1,475,021 thousand, the annualized payout ratio approximates 35.1% using the full-year dividend forecast, which is sustainable relative to earnings. Dividend payments during the nine-month period totaled 41.2B yen. Share repurchases were minimal at essentially zero yen, resulting in a total return ratio approximately equal to the payout ratio of 35.1%. The company maintains a conservative dividend policy with significant retained earnings of 1,084.4B yen, providing ample buffer for dividend sustainability. However, free cash flow of -173.8B yen indicates dividends currently exceed cash generation after investments, necessitating debt financing or cash reserves to fund distributions alongside growth investments.
Working capital deterioration represents the most immediate financial risk, with operating working capital turnover extending to 321 days versus an industry median of 111.5 days. Inventory turnover stretched to 319 days (industry median: 112 days) and receivables turnover to 94 days (industry median: 85 days), indicating significant capital trapped in operations. This inefficiency constrains cash generation and could pressure liquidity if not reversed, particularly given the short-term debt increase to 299.8B yen against cash holdings of 238.0B yen.
Goodwill and intangible asset impairment risk has intensified following the OrganOx acquisition, with total goodwill and intangibles reaching 800.5B yen (+255.3B yen, +46.8% YoY), representing 35.5% of total assets. The company already recognized 4.8B yen in impairment losses during Q3 related to a discontinued pharmaceutical project. Given the substantial amortization burden of 17.1B yen quarterly for acquired intangibles and execution risks inherent in M&A integration, future impairment charges could materially impact reported profitability.
Refinancing and interest rate risk emerged as short-term bonds and borrowings surged to 299.8B yen while long-term borrowings decreased to 99.9B yen, creating a maturity concentration requiring near-term refinancing. With interest paid of 1.9B yen quarterly, rising interest rates could increase financing costs. The debt-to-equity ratio remains manageable at 0.26x, but the shift toward short-term debt structure increases vulnerability to credit market disruptions or rates volatility.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: Operating margin 17.4% significantly outperforms the industry median of 8.9% (75th percentile: 12.7%), positioning the company in the top quartile. Net profit margin of 13.2% substantially exceeds the industry median of 6.5% (75th percentile: 9.4%), reflecting superior cost management and product pricing power. ROE of 7.2% exceeds the industry median of 5.8%, though remains below the 75th percentile of 8.4%, suggesting room for further improvement in capital efficiency.
Financial Health: Equity ratio of 67.5% compares favorably to the industry median of 63.8%, indicating a more conservative balance sheet structure than peers. However, current ratio metrics are constrained by the significant short-term debt increase. Financial leverage of 1.48x aligns closely with the industry median of 1.53x, confirming a peer-appropriate capital structure.
Efficiency: Asset turnover of 0.368 falls materially below the industry median of 0.56 (25th percentile: 0.41), highlighting asset utilization as the primary efficiency gap. Operating working capital turnover of 321 days significantly exceeds the industry median of 111.5 days (75th percentile: 144 days), representing a critical operational deficiency. Inventory turnover of 319 days drastically underperforms the median of 112 days, indicating substantial inventory management challenges. Revenue growth of 7.7% YoY exceeds the industry median of 2.8% (75th percentile: 8.8%), demonstrating strong top-line momentum relative to peers.
※ Industry: Manufacturing (N=105 companies), Comparison: FY2025-Q3, Source: Proprietary analysis
The company demonstrates strong profitability fundamentals with operating margin of 17.4% and net profit margin of 13.2%, both significantly exceeding industry benchmarks, indicating sustainable competitive advantages in pricing power and operational efficiency. The Cardiac and Vascular segment's 26.0% margin particularly highlights premium product positioning. Consecutive revenue growth at 7.7% YoY, accelerating from normalized industry growth rates, combined with operating leverage expanding margins, signals successful market share gains and product portfolio strength.
However, structural working capital deterioration presents a critical near-term challenge requiring immediate management attention. Operating working capital cycle of 321 days, inventory turnover of 319 days, and receivables turnover of 94 days all substantially exceed industry norms, indicating systemic inefficiencies that constrain cash generation despite strong profitability. This inefficiency, combined with negative free cash flow of -173.8B yen, creates a disconnect between earnings quality and cash availability. The aggressive M&A strategy, evidenced by 800.5B yen in goodwill and intangibles (+46.8% YoY), positions the company for long-term growth but introduces integration execution risks and potential future impairment charges, particularly given the 4.8B yen impairment already recognized this quarter. Management's ability to successfully integrate OrganOx while improving working capital efficiency will be critical determinants of sustainable value creation. The shift toward short-term debt financing (299.8B yen) to fund growth investments while maintaining dividends creates refinancing risk that warrants monitoring, despite the conservative 67.5% equity ratio providing a financial cushion.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.